查詢結果分析
來源資料
相關文獻
- 鼻咽癌之放射線治療﹣﹣225 例病患者之研究分析
- 以螢光透視錄影吞嚥檢查評估鼻咽癌患者因放射線治療所致之吞嚥功能異常
- 鼻咽癌經放射線治療後的顳葉壞死
- 分析物理治療雜誌文章特性:1990-1999
- 一位鼻咽癌病患放射線合併化學治療之護理經驗
- An Effective, Efficient and Safe Method to Deliver a Modified 3-D Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
- 探討接受體外放射線治療的鼻咽癌患者之生活品質
- Measurement of the Radiation Doses Absorbed by Jaw Bones during Irradiation of Nasopharyngeal Cancers
- The Characteristics of Dynamic Wedge Factors for 6MV and 18 MV Photon Beams
- 鼻咽癌病患放射治療中斷的原因及分析
頁籤選單縮合
題 名 | 鼻咽癌之放射線治療﹣﹣225 例病患者之研究分析 |
---|---|
作 者 | 蘇志中; | 書刊名 | 醫學研究 |
卷 期 | 9:1 1988.07[民77.07] |
頁 次 | 頁45-54 |
分類號 | 416.879 |
關鍵詞 | 分析; 放射線; 治療; 研究; 病患者; 鼻咽癌; |
語 文 | 中文(Chinese) |
中文摘要 | 三軍總醫院放射腫瘤部自民國65年元月至71年9月,共有未遠端轉移之鼻咽癌患者225例,並接受單獨放射線治療。其中男性158例死,女性67例,年齡分佈由14歲至75歲,平均年齡為45歲。所有患者在治療前均經組織病理切片加以證實,其中鱗狀上皮癌佔61.4%,而未分化癌佔37.7%。所有患者均接受根除性分程(split-course)放射線治療,而治療劑量為在八週內給予鼻咽部位7000厘葛雷(cGy),而在兩側頸部及鎖骨上下寫依其淋巴腺侵犯程度之不同在五至七週內給予5000~7000厘葛雷,但在劑量達到4000厘葛雷時,給病人休息二至三星期。除22位患者未持續門診追踪外,其餘均追踪滿5年。依其期別之不同,其5年保險存活率為:第I期,94.4%;第II期,77.8%;第III期,70.3%及第IV期,53.6%。本文同時也對一些預後因素進行分析,發現期別及頸部切開手術會影響預後,至於性別、年齡及組織病理形態之影響則無統計上的意義。 |
英文摘要 | From January 1976 to September 1982, 225 consecutive patients with a histologically confirmed malignant tumor of the nasopharynx were evaluated and treated by definite megavoltage irradiation in the Department of Radiation oncology of the Tri-Service General Hospital. Patients with known distant metastases at presentation (M1) were excluded from this study analysis. The study was comprised of 158 males and 67 females their ages ranged from 14 to 75 years (mean age, 45 years). The primary tumors were histologically classified into two inajor types, squamous cell carcinoma in 61.4% and undifferentiated carcinoma in 27.1%. All patients were put on a split-course treatment protocol which included a 2-3 week interruption when the tumor dose reached 4000 cGy and a minimal tumor dose of 7000 cGy in 35 increments for 10-11 weeks to the primary site. In addition, the neck and supraclavicular fossae received a basic tumor dose of 5000 cGy. If there were palpable lymph nodes, an additional 1000-2000 cGy were given. All patients, but 22, had 5-year minimum follow-up. Five-year acturial survival rate according to stages were as follows: stage I, 94.4%; stage II, 77.8%; stage III, 70.3%; and stage IV, 39.4%. The purpose of analysis was to determine patient and tumor factor influencing survival. In our study, the factors influencing survival included stage an dcervival lymphnode biopsy. On the other hand, no significant patient factor was observed which influenced survival. |
本系統中英文摘要資訊取自各篇刊載內容。